acastipharma.com - צמיחת רווחי EPS רבעונית ACST
Acasti Pharma (ACST) relies on innovative drug delivery methods to combat rare pathologies. Patent protection of formulas curbs competition, although a capital deficit weakens the firm's position. Geopolitical tensions and disruptions in reagent supplies are hindering global tests. The quarterly percentage change in EPS reflects net profit dynamics, where the current value is 56.20, revealing the margin's resilience to costs.
%20%D7%A9%D7%99%D7%A0%D7%95%D7%99%20%D7%91%D7%A8%D7%95%D7%95%D7%97%20%D7%A0%D7%A7%D7%99%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%9E%D7%A9%D7%A0%D7%94%20%D7%9C%D7%A9%D7%A0%D7%94%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwejrfjc.e5f-7d7lczk&start=20220704&end=20261113&filename=GURU_Markets_-_ACST_-_Acasti-Pharma_-_Year-over-year-net-earnings-per-share-change-for-the-last-twelve-months "ACST Acasti Pharma Inc.: צמיחת רווח נקי למניה משנה לשנה ב-12 החודשים האחרונים בטווח 04.07.2022 - 28.10.2024 | 👁️GURU.Markets👁️")
Acasti Pharma (ACST) - פילוחי מדדים ודוחות פיננסיים
Quarterly EPS growth measures the dynamics of net income per share compared to the same period last year, reflecting the efficiency of value generation for shareholders. Analyzing the current quarterly EPS rate allows for an assessment of how licensing revenues and Acasti Pharma (ACST) developments in treating cardiac pathologies can ensure the business's financial stability amidst market volatility.
